SWOG clinical trial number
SWOG-8796
Combination Chemotherapy for Advanced Hodgkin's Disease
Closed
Phase
Published
Abbreviated Title
Combination Chemotherapy for Advanced Hodgkin's Disease
Activated
12/01/1987
Closed
08/01/1989
Research committees
Lymphoma
Publication Information Expand/Collapse
1998
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year result of the intergroup trial.
1991
A randomized phase III trial of MOPP/ABV Hybrid vs. sequential MOPP-ABVD in advanced Hodgkin's disease: Preliminary results of the intergroup trial.
Other Clinical Trials
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase